Abcam, ab200827, Anti-Androgen receptor variant 5,6,7es antibody [EPR15657]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal Androgen receptor variant 5,6,7es antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 5 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR15657,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This ARv567es antibody (Ab200827, clone EPR15657) is a rabbit monoclonal antibody against Human Androgen receptor variant 5,6,7es (aa 700 to the C-terminus). This antibody does not react with AR-FL.

Product details:
Anti-ARv567es RabMAb product (Clone EPR15657) has been highlighted in the following poster:
Identification of ARv567es expression profile in the prostate cancer clinical samples with a newly developed antibody
For ARv7 specific RabMAb antibody -
ab198394
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The androgen receptor variant 567es often shortened to AR-V567es is a splice variant of the androgen receptor (AR) integral in regulating gene expression in response to androgens. This receptor plays a role in the signal transduction of androgens like testosterone and dihydrotestosterone. The molecular weight of this variant is around 110 kDa. AR-V567es lacks the ligand-binding domain present in the full-length androgen receptor which enables its activity even in the absence of natural androgens. This variant expresses mainly in prostate tissue and some other tissues sensitive to androgens.
Biological function summary
The androgen receptor variant 567es acts as a transcription factor influencing a range of cellular processes including proliferation and survival. It remains involved in the androgen receptor signaling axis playing a vital role even when standard androgen receptor pathways are downregulated or inhibited. Although it functions independently AR-V567es may interact with other coregulators to influence gene regulation. It does not form part of a larger protein complex but works independently to modulate specific androgen-responsive genes maintaining cellular growth and differentiation signals.
Pathways
This androgen receptor variant engages in the androgen receptor signaling pathway which remains fundamental for the development and function of male characteristics. It is also critical in maintaining the proliferation of prostate cells. Related proteins in these pathways include the full-length androgen receptor and the steroid receptor coactivators which help modulate gene expression. The absence of a traditional ligand-binding domain in AR-V567es confers distinct roles compared to its ligand-dependent counterparts.
Androgen receptor variant 567es is notably linked to prostate cancer where it contributes to the progression of castration-resistant prostate cancer (CRPC). This variant's ability to be active without typical androgen binding enables continued cancer cell survival and proliferation despite androgen-deprivation therapies. Additionally the presence of AR-V567es connects with alterations in the androgen receptor network where it interacts with other variant receptors to drive resistance to conventional anti-androgen treatments. This makes it a significant target for developing new therapeutic strategies against CRPC.